Israeli startup's personalised cell therapy gets FDA fast-track designation
BioGenCell received FDA Fast Track Designation for BGC101, a personalized cell therapy for severe CLTI. BGC101, using the TRACT platform, regenerates damaged tissue, offering hope to patients with no other treatment options. The designation follows promising clinical results from Phase 2 trial enrollment across the US, Europe, and Israel.
Related News
Israeli startup's personalised cell therapy gets FDA fast-track designation
BioGenCell received FDA Fast Track Designation for BGC101, a personalized cell therapy for severe CLTI. BGC101, using the TRACT platform, regenerates damaged tissue, offering hope to patients with no other treatment options. The designation follows promising clinical results from Phase 2 trial enrollment across the US, Europe, and Israel.